S&P/ASX 200 Index (ASX: XJO) shares are down 0.72% to 8,666.9 points on Tuesday.
The market is cautious as it continues to wait for further news on peace negotiations between the US and Iran.
Among the 11 market sectors, technology shares are in the lead, up 3.3%, while ASX REITs are the laggard, down 1.8%.
Meanwhile on the The Bull this week, two experts give us their views on three ASX 200 shares.
Let's check them out.
Image source: Getty Images
Commonwealth Bank of Australia (ASX: CBA)
The CBA share price is $161.02, down 1.4% today, and down 0.6% in the calendar year to date (YTD).
John Athanasiou from Red Leaf Securities has a hold rating on this ASX 200 bank share this week.
Athanasiou explains:
CBA remains the highest quality franchise in Australian banking, supported by its dominant deposit base, strong digital ecosystem and industry leading profitability.
Earnings remain resilient, but growth is moderating as mortgage competition intensifies and credit expansion normalises.
Credit quality is stable and dividends remain highly reliable, reinforcing its defensive appeal.
However, the key issue is valuation, with the stock trading at a significant premium to domestic and global peers.
Much of the quality and stability is already priced in, leaving limited upside without a material macro or earnings surprise to the upside.
Wesfarmers Ltd (ASX: WES)
The Wesfarmers share price is $78.90, down 1.1% today, and down 3.5% YTD.
Philippe Bui from Medallion Financial Group puts a sell rating on this ASX 200 consumer discretionary share this week.
Bui says:
Wesfarmers is a high quality business, but the outlook is softening, in our view.
A deteriorating consumer environment and sticky inflation are pressuring forward earnings, while Amazon's growing penetration across core retail categories is an intensifying competitive threat that shows no signs of abating.
Saluda Medical Inc (ASX: SLD)
The Saluda Medical share price is 43 cents, up 10.3% on no news today, and down 70% YTD.
Bui has a buy recommendation on this ASX healthcare share, and comments:
Saluda makes the Evoke spinal cord stimulator — the only closed loop device that automatically adjusts pain therapy in real time.
Clinical results are strong, with 90 per cent of patients preferring it to traditional systems.
Global revenue grew by 34 per cent in the third quarter of fiscal year 2026 when compared to the prior corresponding period.
Full year guidance has been upgraded twice since its initial public offering in calendar year 2025.
Given the share price fall since listing in December 2025, the valuation is compelling at current levels, in our view.
With no closed loop offering from competitors, acquisition interest is a real possibility.
